Crataegus - Dr Willmar Schwabe Pharmaceuticals

Drug Profile

Crataegus - Dr Willmar Schwabe Pharmaceuticals

Alternative Names: Crataegutt; WS 1442

Latest Information Update: 22 Jul 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dr. Willmar Schwabe Pharmaceuticals
  • Class Cardiac glycosides; Cardiotonics; Heart failure therapies; Phytotherapies
  • Mechanism of Action Free radical scavengers; Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure

Most Recent Events

  • 22 Jul 2002 A study has been added to the adverse events and Heart Failure therapeutic trials sections
  • 03 Mar 2000 A study has been added to the adverse events and the Heart Failure therapeutic trials sections
  • 02 Jun 1998 Launched for Heart failure in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top